– CHINA, Hangzhou – Hangzhou Qihan Biotech Co., Ltd., an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, today announced the appointment of Naxin Yao to its Board as an Independent Director.
About Naxin Yao
Mr. Yao is a highly accomplished and respected business leader with extensive experience in corporate management, strategic planning, and global vision.
Previously, he served as the first General Manager of Alibaba USA Corporation. In 2002, he returned to China and founded Focused Photonics (Hangzhou) Inc., a Chinese high-tech platform-based enterprise specializing in high-end analytical instruments as its core business, successfully went public (300203. SZ) in 2011. In 2012, with several returned overseas entrepreneurs and professional investors, Mr. Yao co-founded Haibang Venture, a VC/PE firm focusing on life health and innovative technologies. It was China’s first venture capital fund to encourage and support young overseas returnees in entrepreneurship. In 2015, Mr. Yao co-founded New Horizon Health, a pioneer and market leader in China’s cancer screening market for early detection of high-incidence cancers, which later became the “first cancer screening stock in China” in 2021. (06606.H.K.)
“I am honored to join the Board of Directors of Qihan Biotech and be part of a bright company driven by technology and innovation. With an independent research and development platform, it can inspire more young people to engage in the field of innovative science and medicine. I believe that young scientists can showcase their talents to their full potential in Qihan and create products that cure diseases and save lives,” said Naxin Yao.
Mr. Yao completed his B.S. in Cell Biology and Genetic Engineering from Peking University, his M.S. in Molecular Biology from UC Berkeley, and his master’s degree in management from Stanford Graduate School of Business.
About Qihan Biotech
Qihan Biotech is a biotechnology company applying genome editing technology to develop novel cell therapies and organs for transplantation. The company’s mission is to use high-throughput, multiplexable genome editing combined with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other complex medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised two financing rounds. It has multiple products at different stages of development, including QN-019a, which had already received IND approval from China NMPA to treat CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Qihan’s deep scientific experience and technology advancements have enabled the company to create cutting-edge cell therapy products. Qihan Biotech is headquartered in Hangzhou, China.
For more information: https://www.qihanbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
